Cost Study of the PlasmaJet Surgical Device Versus Conventional Cytoreductive Surgery in Patients With Advanced-Stage Ovarian Cancer.
Gatske Nieuwenhuyzen-de BoerAlexandra J L M GeraerdsMarieke H van der LindenHelena C van DoornSuzanne PolinderHeleen van BeekhuizenPublished in: JCO clinical cancer informatics (2022)
Mean total health care costs of the use of PlasmaJet in CRS were significantly higher than those for conventional CRS. This difference is fully explained by the additional surgery costs of the use of PlasmaJet. However, surgery with the use of the PlasmaJet leads to a significantly higher percentage of complete CRS and a halving of stomas. A cost-effectiveness analysis will be performed once survival data are available (funded by ZonMw, Trial Register NL62035.078.17).